This tutorial review describes recent progress in the development of homogeneous catalytic methodology for the direct generation of hydrogen gas from formic acid and alcohols.

Catalytic anticancer metallodrugs active at low doses could minimize side-effects, introduce novel mechanisms of action that combat resistance and widen the spectrum of anticancer-drug activity. Here we use highly stable chiral half-sandwich organometallic Os(II) arene sulfonyl diamine complexes, [Os(arene)(TsDPEN)] (TsDPEN, N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine), to achieve a highly enantioselective reduction of pyruvate, a key intermediate in metabolic pathways. Reduction is shown both in aqueous model systems and in human cancer cells, with non-toxic concentrations of sodium formate used as a hydride source. The catalytic mechanism generates selectivity towards ovarian cancer cells versus non-cancerous fibroblasts (both ovarian and lung), which are commonly used as models of healthy proliferating cells. The formate precursor N-formylmethionine was explored as an alternative to formate in PC3 prostate cancer cells, which are known to overexpress a deformylase enzyme. Transfer-hydrogenation catalysts that generate reductive stress in cancer cells offer a new approach to cancer therapy.

No abstract

Ruthenium dimer 6 (readily available in two steps from TsDPEN) is converted directly to monomeric asymmetric transfer hydrogenation catalyst 3 in situ under the conditions employed for ketone reduction. Catalyst 3 is a significantly more active catalyst for this application than the untethered derivative, exhibits higher enantioselectivities across a range of substrates, and appears to be highly stable to the reaction conditions. It is active at loadings of as low as 0.01 mol %, and reductions at the 0.1 mol % level are complete within 20 min at 80 degrees C without significant loss of enantioselectivity.

No abstract

The decomposition of a HCO2H/Et3N azeotrope to a mixture of hydrogen and carbon dioxide may be catalyzed by a number of Ru(III) and Ru(II) complexes with high efficiency at ca. 120 °C. Evidence that suggests that the precatalyst may in each case be a common ruthenium dimer has been obtained through 1H NMR and X-ray crystallographic studies of the complexes formed in situ and of analysis of the gases generated in the reaction using FTIR and gas chromatography methods.

N-Alkylated TsDPEN derivatives bearing a small alkyl group act as highly efficient ligands in Ru(II) complexes for the asymmetric transfer hydrogenation of imines and ketones. A larger alkyl group serves to significantly reduce the activity of the catalyst; however, high enantiomeric excesses are still obtained. An X-ray crystal structure of the N-benzyl derivative reveals a conformation that permits hydrogen transfer through a six-membered transition state. A transition state structure for the imine reduction process is proposed.

Ruthenium dimer 4 is converted directly to monomeric asymmetric transfer hydrogenation catalyst 2 under the conditions employed for ketone reduction. Using 0.25 mol % of either 4 or 0.5 mol % of 2 in formic acid/triethylamine, it is possible to achieve ketone reduction in quantitative conversion and with ee's as high as 98%. Complex 2 is a robust "single-reagent" catalyst which offers significant scope for modification toward specific substrates. The synthesis and applications of an analogous complex derived from (1R,2S)-norephedrine are also described.